NZ235221A - Inhalatory composition comprising salmeterol and fluticasone propionate - Google Patents

Inhalatory composition comprising salmeterol and fluticasone propionate

Info

Publication number
NZ235221A
NZ235221A NZ235221A NZ23522190A NZ235221A NZ 235221 A NZ235221 A NZ 235221A NZ 235221 A NZ235221 A NZ 235221A NZ 23522190 A NZ23522190 A NZ 23522190A NZ 235221 A NZ235221 A NZ 235221A
Authority
NZ
New Zealand
Prior art keywords
salmeterol
fluticasone propionate
composition
inhalation
physiologically acceptable
Prior art date
Application number
NZ235221A
Other languages
English (en)
Inventor
James Barry Douglas Palmer
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27264677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ235221(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898920392A external-priority patent/GB8920392D0/en
Priority claimed from GB898923644A external-priority patent/GB8923644D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NZ235221A publication Critical patent/NZ235221A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
NZ235221A 1989-09-08 1990-09-07 Inhalatory composition comprising salmeterol and fluticasone propionate NZ235221A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898920392A GB8920392D0 (en) 1989-09-08 1989-09-08 Medicaments
GB898923644A GB8923644D0 (en) 1989-10-20 1989-10-20 Medicaments
SG166294A SG166294G (en) 1989-09-08 1994-11-18 Inhalation medicaments for treating respiratory disorders

Publications (1)

Publication Number Publication Date
NZ235221A true NZ235221A (en) 1992-11-25

Family

ID=27264677

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ235221A NZ235221A (en) 1989-09-08 1990-09-07 Inhalatory composition comprising salmeterol and fluticasone propionate

Country Status (20)

Country Link
EP (1) EP0416951B1 (en:Method)
JP (1) JP3042867B2 (en:Method)
AT (1) ATE99941T1 (en:Method)
BE (1) BE1003053A3 (en:Method)
CA (1) CA2024916C (en:Method)
CH (1) CH680983C9 (en:Method)
DE (2) DE19975040I2 (en:Method)
DK (1) DK0416951T3 (en:Method)
ES (1) ES2062392T3 (en:Method)
FR (1) FR2651677B1 (en:Method)
HK (1) HK18695A (en:Method)
HU (1) HU211272A9 (en:Method)
IE (1) IE65535B1 (en:Method)
IL (1) IL95590A (en:Method)
IT (1) IT1241996B (en:Method)
LU (1) LU90392I2 (en:Method)
NL (1) NL990012I2 (en:Method)
NZ (1) NZ235221A (en:Method)
PH (1) PH27594A (en:Method)
SG (1) SG166294G (en:Method)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
CA2123909C (en) * 1991-12-18 2002-10-01 Christer Carl Gustav Carling New combination of formoterol and budesonide
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DE59904488D1 (de) 1998-11-13 2003-04-10 Jago Res Ag Muttenz Trockenpulver zur inhalation
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
JP2003509359A (ja) 1999-09-11 2003-03-11 グラクソ グループ リミテッド プロピオン酸フルチカゾンの医薬製剤
JP2003518484A (ja) * 1999-12-24 2003-06-10 グラクソ グループ リミテッド サルメテロールおよびプロピオン酸フルチカゾンの医薬用エアゾル製剤
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
BRPI0113042B8 (pt) * 2000-08-05 2021-05-25 Glaxo Group Ltd composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
EP1366025B1 (en) 2001-03-08 2007-06-27 Glaxo Group Limited Agonists of beta-adrenoreceptors
DE60224172T2 (de) 2001-03-22 2008-12-04 Glaxo Group Ltd., Greenford Formanilid-derivative als beta2-adrenorezeptor-agonisten
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
JP4446661B2 (ja) 2001-04-30 2010-04-07 グラクソ グループ リミテッド 抗炎症性の、１７α位に環状エステル基を有するアンドロスタンの１７β−カルボチオ酸エステル誘導体
PT2042168E (pt) 2001-09-14 2014-01-03 Glaxo Group Ltd Formulação de inalação compreendendo derivados de fenetanolamina para o tratamento de doenças respiratórias
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
EP1757281A3 (en) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
WO2003066033A1 (en) † 2002-02-04 2003-08-14 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
JP2005519110A (ja) * 2002-03-04 2005-06-30 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規なケイ皮酸塩、その調製方法及び医薬品としての使用
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
WO2004052374A1 (en) 2002-12-12 2004-06-24 Altana Pharma Ag Combination medicament
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
AU2003254429A1 (en) 2003-08-06 2005-02-25 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
RU2006136025A (ru) * 2004-03-12 2008-04-20 Сипла Лимитед (In) Ингаляционные композиции
JP4621736B2 (ja) 2004-07-16 2011-01-26 アルミラル ソシエダツド アノニマ 粉末薬剤を投与するための吸入器、及びこの吸入器と共に使用するための粉末カートリッジシステム
CN101600469B (zh) 2006-12-22 2013-10-23 奥米罗有限公司 药粉吸入装置
CN101744792B (zh) * 2008-12-17 2013-04-17 张凯 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺
KR101926060B1 (ko) 2009-05-29 2018-12-06 펄 테라퓨틱스 인코포레이티드 활성제의 호흡기 전달용 조성물, 및 연관된 방법 및 시스템
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
US20160158149A1 (en) * 2013-04-29 2016-06-09 Sanofi Sa Inhalable Pharmaceutical Compositions and the Inhaler Devices Containing Them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
FR2588474B1 (fr) * 1985-10-16 1987-11-27 Cird Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste

Also Published As

Publication number Publication date
DE19975040I2 (de) 2006-07-13
HK18695A (en) 1995-02-17
SG166294G (en) 1995-06-16
CA2024916A1 (en) 1991-03-09
PH27594A (en) 1993-08-31
IT1241996B (it) 1994-02-02
DE69005951T2 (de) 1994-05-26
EP0416951A1 (en) 1991-03-13
NL990012I2 (nl) 1999-09-01
IT9048260A0 (it) 1990-09-07
IL95590A (en) 1996-06-18
FR2651677B1 (fr) 1993-08-06
CH680983A5 (en:Method) 1992-12-31
BE1003053A3 (fr) 1991-11-05
CH680983C9 (en:Method) 2008-08-15
JP3042867B2 (ja) 2000-05-22
DE69005951D1 (de) 1994-02-24
LU90392I2 (fr) 1999-06-28
FR2651677A1 (fr) 1991-03-15
CA2024916C (en) 2002-07-09
IE65535B1 (en) 1995-11-01
EP0416951B1 (en) 1994-01-12
CH680983C1 (en:Method) 2008-06-25
ES2062392T3 (es) 1994-12-16
IT9048260A1 (it) 1992-03-07
IL95590A0 (en) 1991-09-16
ATE99941T1 (de) 1994-01-15
IE903256A1 (en) 1991-03-13
JPH03167120A (ja) 1991-07-19
NL990012I1 (nl) 1999-07-01
HU211272A9 (en) 1995-11-28
DK0416951T3 (da) 1994-02-14

Similar Documents

Publication Publication Date Title
US5270305A (en) Medicaments
CA2024916C (en) Respiratory disorder medicaments comprising salmeterol and fluticasone propionate
US5208226A (en) Medicaments
EP0416950B1 (en) Medicaments
AU673660B2 (en) New combination of formoterol and budesonide
AU693632B2 (en) Proliposome powders for inhalation
RU2327450C2 (ru) Фармацевтические продукты и композиции, содержащие специфические антихолинергические средства, агонисты бета-2 и кортикостероиды
US6369115B1 (en) Stabilized powder formulations
WO1997039745A1 (en) Use of inhaled retinoids in the prevention of cancer
CY1817A (en) Inhalation medicaments for treating respiratory disorders
WO2000053187A1 (en) New combination of formoterol and mometasone in a pharmaceutical composition for treating respiratory disorders, such as asthma, rhinitis and copd
EP0613371B1 (en) New combination of formoterol and budesonide
KR100294834B1 (ko) 호흡기질환치료용제약조성물
KR20060135873A (ko) 살메테롤 흡입 제제
MXPA98004357A (en) New combination
MXPA97004406A (en) Proliposomas powders for inhalac

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
S38A Application for proceedings under section 38 (amendment of specification with leave of commissioner)

Free format text: BY WAY OF DISCLAIMER AND EXPLANATION

S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended